isoniazid will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. acalabrutinib increases levels of doxorubicin by Other (see comment). Cancer. Avoid or Use Alternate Drug. atorvastatin increases levels of naldemedine by P-glycoprotein (MDR1) efflux transporter. Unclear on net effect of pantoprazole action due to opposing effects by CYP450 enzymes; monitoroxcarbazepine will increase the level or effect of pantoprazole by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor. Use Caution/Monitor. fedratinib will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid. atorvastatin will increase the level or effect of lapatinib by P-glycoprotein (MDR1) efflux transporter. 3 This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to Avoid or Use Alternate Drug. methotrexate, brexucabtagene autoleucel. Use Caution/Monitor. Applies only to oral form of both agents. Use Caution/Monitor. pantoprazole will increase the level or effect of clobazam by affecting hepatic enzyme CYP2C19 metabolism. Bremelanotide may slow gastric emptying and potentially reduces the rate and extent of absorption of concomitantly administered oral medications. Darolutamide is a BCRP inhibitor. Monitor Closely (1)pantoprazole will decrease the level or effect of iron sucrose by increasing gastric pH. Avoid or Use Alternate Drug. Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers.Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Risk for drug interactions with methotrexate is greatest during high-dose methotrexate therapy, it has been recommended that any of these drugs be used cautiously with methotrexate even when methotrexate is used in low doses. Serious - Use Alternative (1)voxelotor will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Darolutamide is a BCRP inhibitor. Increased risk of rhabdomyolysis (incl a fatality). Ivacaftor and its M1 metabolite has the potential to inhibit P-gp; may significantly increase systemic exposure to sensitive P-gp substrates with a narrow therapeutic index. Use Caution/Monitor. dosage, form, labeller, route of administration, and marketing period. Avoid or Use Alternate Drug. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors. Modify Therapy/Monitor Closely. Contact the applicable plan Notify your doctor right away if redness, blistering, sores, pain, or swelling occur at or near the injection site.Doxorubicin may cause heart problems, including possibly fatal heart failure. [citation needed]. informational and educational purposes only. Use Caution/Monitor. Use Caution/Monitor. Serious - Use Alternative (1)doxorubicin, tofacitinib. cyclosporine will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.levoketoconazole will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Access drug product information from over 10 global regions. Modify Therapy/Monitor Closely. The cream and ointment are not effective for nail infections. 2014;2014:357027. doi: 10.1155/2014/357027. Use Caution/Monitor. Use Caution/Monitor. Access now. Absorption. Minor/Significance Unknown. Monitor Closely (2)glecaprevir/pibrentasvir will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Applies only to oral form of both agents. Use Caution/Monitor. Use Caution/Monitor. Avoid use when taking any oral drug that is dependent on threshold concentrations for efficacy. Use Caution/Monitor. immunosuppressive effects; risk of infection. methotrexate, ciltacabtagene autoleucel. Avoid or Use Alternate Drug. Monitor Closely (1)tafamidis will increase the level or effect of methotrexate by Other (see comment). Monitor Closely (1)methotrexate decreases effects of tetanus toxoid adsorbed or fluid by pharmacodynamic antagonism. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Avoid or Use Alternate Drug. Either increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. [, Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH: The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. Use Caution/Monitor. Contraindicated. sofosbuvir/velpatasvir will increase the level or effect of nitrofurantoin by Other (see comment). Coadministration of glecaprevir/pibrentasvir with atorvastatin is not recommended. Minor/Significance Unknown. Applies only to oral form of both agents. Use Caution/Monitor. fosphenytoin will decrease the level or effect of pantoprazole by affecting hepatic enzyme CYP2C19 metabolism. Minor/Significance Unknown. CrCl . 9. Use Caution/Monitor. Serious - Use Alternative (1)lasmiditan increases levels of nitrofurantoin by Other (see comment). Monitor Closely (1)conivaptan will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)methotrexate increases levels of theophylline by unknown mechanism. Use Caution/Monitor. Comment: OATP1B1 inhibitors may increase risk of myopathy. Vivjoa. methotrexate increases effects of warfarin by unspecified interaction mechanism. Monitor Closely (1)tafamidis will increase the level or effect of doxorubicin by Other (see comment). Avoid vaccination during chemotherapy or radiation therapy if possible because antibody response might be suboptimal. Immunosuppressants also increase risk of infection with concomitant live vaccines. Use Caution/Monitor. Use Caution/Monitor. Concomitant administration of methotrexate can decrease the immunological response of vaccines. Either increases toxicity of the other by unknown mechanism. Use Caution/Monitor. tafamidis meglumine will increase the level or effect of atorvastatin by Other (see comment). Use Caution/Monitor. . Greater risk in pts. Canada residents can call a provincial poison control center. Serious - Use Alternative (1)nitrofurantoin, pretomanid. Minor/Significance Unknown. Immunization with live virus vaccines is generally not recommended. Monitor Closely (1)mipomersen, methotrexate. Monitor Closely (1)acalabrutinib increases levels of nitrofurantoin by Other (see comment). Access now. Use Caution/Monitor. Coadministration may increase systemic exposure of drugs that are substrates of these transporters. sodium citrate/citric acid decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Comment: OATP1B1 inhibitors may increase risk of myopathy. Use Caution/Monitor. commonly, these are "preferred" (on formulary) brand drugs. Monitor Closely (1)oteseconazole will increase the level or effect of nitrofurantoin by Other (see comment). Access now. Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. Either increases toxicity of the other by pharmacodynamic synergism. Coadministration with immunosuppressive therapies may increase the risk of additive immune effects during therapy and in the weeks following administration. Use Caution/Monitor. Use Caution/Monitor.Minor (1)atorvastatin will increase the level or effect of armodafinil by P-glycoprotein (MDR1) efflux transporter. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid. Take with a full glass of water. Minor/Significance Unknown. Darolutamide is a BCRP inhibitor. Monitor Closely (1)ampicillin increases levels of methotrexate by decreasing renal clearance. Dolutegravir is a HIV-1 intergrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). Comment: Lasmiditan inhibits BCRP in vitro. [, Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Avoid coadministration of pazopanib with drugs that raise gastric pH; consider short-acting antacids in place of PPIs and H2 antagonists; separate antacid and pazopanib dosing by several hours. Monitor Closely (1)doxorubicin will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Blood. pantoprazole increases toxicity of theophylline by Other (see comment). The absence of an interaction does not necessarily mean no interactions exist. Use Caution/Monitor. Glecaprevir/pibrentasvir may increase plasma concentration of P-gp and BCRP substrates. Selective COX 2 inhibitors are believed to have minimal interaction. Use Caution/Monitor. Sublingual dosing leads to a C max of 10ng/mL, with a T max of 50min, and an AUC of 25ng*h/mL. Use Caution/Monitor. methotrexate increases effects of fingolimod by immunosuppressive effects; risk of infection. Acalabrutinib solubility decreases with increasing gastric pH. Enhanced risk of peripheral neuropathy. Use Caution/Monitor. Oteseconazole: The serum concentration of Allopurinol can be increased when it is combined with Oteseconazole. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events. Use Caution/Monitor. bosutinib increases levels of methotrexate by P-glycoprotein (MDR1) efflux transporter. secobarbital will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. marijuana will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Active Moieties . atorvastatin increases toxicity of pazopanib by P-glycoprotein (MDR1) efflux transporter. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir. Use Caution/Monitor. Avoid or Use Alternate Drug. Concomitant use of fostamatinib may increase concentrations of P-gp substrates. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir. trastuzumab, methotrexate. Monitor Closely (1)trimagnesium citrate anhydrous decreases levels of nitrofurantoin by inhibition of GI absorption. Monitor Closely (1)pantoprazole will decrease the level or effect of mycophenolate by increasing gastric pH. Modify Therapy/Monitor Closely. Comment: OATP1B1 inhibitors may increase risk of myopathy. Monitor Closely (1)efavirenz will decrease the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Combination may increase risk of myelosuppression. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvcHJvdG9uaXgtcGFudG9wcmF6b2xlLTM0MjAwMQ==, View explanations for tiers and Monitor Closely (1)nefazodone will increase the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. The renal tubule adenoma/carcinoma, renal pelvis transitional cell neoplasms, the urinary bladder and urethra transitional cell papillomas, the small intestine adenocarcinomas, the parathyroid glands adenomas, the benign and malignant medullary tumors of the adrenal glands and the non-glandular stomach papillomas/carcinomas were noted at 60 mg/kg/day. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. Minor (1)atorvastatin decreases levels of coenzyme Q10 by unspecified interaction mechanism. Serious - Use Alternative (1)tocilizumab and methotrexate both increase immunosuppressive effects; risk of infection. Consider reducing the dosage of P-gp substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. Use Caution/Monitor. Tell your doctor right away if you develop any signs of infection (such as sore throat that doesn't go away, fever, chills), unusual tiredness, or easy bleeding/bruising.Your doctor will closely monitor you while you are being treated with this medication.Different types of this medication work in different ways. Monitor Closely (1)cisplatin and methotrexate both increase nephrotoxicity and/or ototoxicity. Tell the doctor right away if you notice wheezing or trouble breathing in the child.A very serious allergic reaction to this drug is rare. dronedarone will increase the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with fostamatinib. If any of these effects continue or worsen, notify your doctor or pharmacist.Doxorubicin may give a reddish color to your urine, tears, and sweat. and formulary information changes. Other (see comment). Minor/Significance Unknown. Use Caution/Monitor. Monitor Closely (1)trastuzumab deruxtecan, methotrexate. Monitor Closely (2)prednisone will decrease the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)meclofenamate increases levels of methotrexate by decreasing renal clearance. Oncologist. methotrexate decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Consider dosage reduction for BCRP substrates if adverse effects are experienced when coadministered. Monitor Closely (1)elagolix will increase the level or effect of methotrexate by P-glycoprotein (MDR1) efflux transporter. Either increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Use Caution/Monitor. Monitor Closely (1)sarecycline will increase the level or effect of methotrexate by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor Closely (1)atorvastatin will increase the level or effect of conjugated estrogens by P-glycoprotein (MDR1) efflux transporter. Monitor for toxicities of P-gp substrates that may require dosage reduction when coadministered with P-gp inhibitors. Use Caution/Monitor. Avoid or Use Alternate Drug. This effect was not observed with istradefylline 20 mg/day. enzalutamide will decrease the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. Otesezonale, a BCRP inhibitor, may increase the effects and risk of toxicities of BCRP substrates. mirabegron will increase the level or effect of doxorubicin by affecting hepatic enzyme CYP2D6 metabolism. Monitor for doxorubicin-induced cardiovascular toxicity. Applies only to oral form of both agents. oteseconazole will increase the level or effect of atorvastatin by Other (see comment). https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvbGlwaXRvci1hdG9ydmFzdGF0aW4tMzQyNDQ2, View explanations for tiers and Use Caution/Monitor. Recent Results Cancer Res. Canada residents can call a provincial poison control center. dronedarone will increase the level or effect of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)fluconazole will increase the level or effect of doxorubicin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Encorafenib (a OATP1B1, OATP1B3, and BCRP inhibitor) may increase the concentration and toxicities of OATP1B1, OATP1B3, and BCRP substrates. atorvastatin increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Arachnoiditis with intrathecal administration, Subacute toxicity with intrathecal administration (paralysis of extremities, cranial nerve palsy, seizure or coma), Demyelinating encephalopathy with cranial irradiation or other systemic chemotherapy, Disorders of lung, interstitial pneumonia (acute, chronic), Atrophy of liver, cirrhosis, hepatic fibrosis or necrosis, elevated liver function tests, hepatic failure, Known hypersensitivity; severe reactions observed, Based on published reports and its mechanism of action, can cause embryofetal toxicity, including fetal death; contraindicated in females with nonmalignant disease, Hypersensitivity reactions, including anaphylaxis, reported; if hypersensitivity occurs, immediately discontinue and institute appropriate therapy, Myelosuppression reported, including severe and life-threatening pancytopenia, anemia, aplastic anemia, leukopenia, neutropenia, and thrombocytopenia; obtain blood counts at baseline and periodically; provide supportive care and withhold, reduce dose, or discontinue methotrexate if needed, GI toxicity may occur, including diarrhea, vomiting, stomatitis, hemorrhagic enteritis, and fatal intestinal perforation; patients with peptic ulcer disease or ulcerative colitis at greater risk; withhold or discontinued for severe GI toxicity and institute supportive care, Pulmonary toxicity reported, including acute or chronic interstitial pneumonitis and irreversible or fatal cases can occur at all dose levels; pulmonary symptoms (especially a dry, non-productive cough) may require interruption of therapy and careful investigation, Pulmonary toxicity reported, including acute or chronic interstitial pneumonitis and irreversible or fatal cases can occur at all dose levels, Secondary malignancies can occur at all dose levels; in some cases, lymphoproliferative disease that occurred during therapy with low-dose methotrexate regressed completely following withdrawal of methotrexate; if lymphoproliferative disease occurs, discontinue and institute appropriate treatment if lymphoma does not regress, Can induce tumor lysis syndrome with rapidly growing tumors; institute appropriate treatment for prevention and management, Can cause impairment of fertility, oligospermia, and menstrual dysfunction; unknown if infertility is reversible; discuss reproduction risks with female and male patients of reproductive potential, Methotrexate can exit slowly from third space accumulations resulting in prolonged terminal plasma half-life and toxicity; evacuate significant third-space accumulations prior injection Concomitant radiation therapy increases risk of soft tissue necrosis and osteonecrosis associated with methotrexate, Serious adverse reactions, including death, have occurred due to medication errors; most commonly, these errors occurred in patients who were taking methotrexate daily when a weekly dosing regimen was prescribed; ensure that patients receive the recommended dosage, Based on published reports and mechanism of action, can cause embryo-fetal toxicity and fetal death when administered to pregnant women, Advise pregnant women with neoplastic diseases of potential risk to fetus; preservative benzyl alcohol can cross placenta; when possible, use preservative-free formulation when methotrexate Injection needed during pregnancy to treat a neoplastic disease, Verify pregnancy status of females of reproductive potential before initiating, Contraindicated in pregnant women with nonmalignant disease, Limited published literature report the presence of methotrexate in human milk in low amounts; no information is available on the effects on breastfed infants or milk production, Because of the potential for serious adverse reactions, including myelosuppression, from methotrexate in breastfed infants, advise women not to breastfeed during therapy and for 1 week after final dose. Monitor for toxicities of the P-gp substrate drug that may require dosage reduction when given concurrently with fostamatinib. Use Caution/Monitor. Monitor Closely (1)bosutinib increases levels of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Epub 2005 Jul 28. Access now. Severe liver toxicity was observed in dogs treated for 2 weeks, with elevated liver enzymes, hepatocellular necrosis, bile duct necrosis, and bile duct hyperplasia. Increased risk of toxicity with higher doses. Minor/Significance Unknown. Monitor serum concentrations. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information). 8 Compared to other H 2 Wait until Abx Tx complete to administer live bacterial vaccine. Access now. Decrease betrixaban dose to 80 mg PO once, then 40 mg PO qDay if coadministered with a P-gp inhibitor. Concomitant administration of NSAIDs with high dose methotrexate has been reported to elevate and prolong serum methotrexate levels, resulting in deaths from severe hematologic and GI toxicity. Information suggests voclosporin (an OATP1B1 inhibitor) may increase in the concentration of OATP1B1 substrates is possible. Serious - Use Alternative (1)pantoprazole will increase the level or effect of riociguat by decreasing metabolism. Low risk of contraceptive failure. Modify Therapy/Monitor Closely. Increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with concurrent administration of high or low doses of methotrexate and penicillins. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. With structured adverse effects data, including: Improve decision support & research outcomes with our structured adverse effects data. quinupristin/dalfopristin will increase the level or effect of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. The dosage and length of treatment are based on your medical condition and response to treatment.If you are using this medication at home, learn all preparation and usage instructions from your health care professional. Redness, pain, or swelling at the injection site may also occur.
Uninstall Teams Command Line, Do You Tip The Owner Of A Salon, Eq Is More Important Than Iq Essay, Mililani Town Association Id Card, Secret Swimming Holes In Banff, Prayer For Difficult Situations At Work, Ipad Pro 11 Bumper Compatible With Magic Keyboard, Bethel Maine Festival, Flexible Work Arrangements Best Practices, Best Maldives Hotel With Baby, Used Machinery In Germany, Civil Rights Act Of 1968, Professional Neurofeedback Equipment,
